Pressmeddelande

  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol reaches 440 patients in global Phase III AGENT study

    GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased…

    by
  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an…

    by
  • Strengthened patent protection for arfolitixorin in Japan

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today…

    by
  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today…

    by
  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced…

    by
  • Isofol’s CEO Ulf Jungnelius has subscribed for all warrants

    GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

    by
  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (Nasdaq First North Premier Growth Market: ISOFOL), today announced that 330 patients…

    by
  • AGENT study update with regards to COVID-19

    GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the…

    by